Robert Z. Orlowski, MD, PhD

home / authors / robert-z-orlowski-md-phd

Articles

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 17th 2021

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

Frequency of Measuring Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 15th 2021

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

Strategies to Monitor Multiple Myeloma

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 10th 2021

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

Goals of Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 8th 2021

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma

Robert Z. Orlowski, MD, PhD

November 15th 2011

Bortezomib (Velcade), the first-in-class inhibitor of the proteasome,[1] or multicatalytic proteinase complex,[2] was originally found to be active against relapsed and relapsed/refractory multiple myeloma as a single agent in phase I through III clinical trials.[3-6

<1 2